MX2018004541A - Descubrimiento iterativo de neoepítopes e inmunoterapia adaptativa y método para ello. - Google Patents

Descubrimiento iterativo de neoepítopes e inmunoterapia adaptativa y método para ello.

Info

Publication number
MX2018004541A
MX2018004541A MX2018004541A MX2018004541A MX2018004541A MX 2018004541 A MX2018004541 A MX 2018004541A MX 2018004541 A MX2018004541 A MX 2018004541A MX 2018004541 A MX2018004541 A MX 2018004541A MX 2018004541 A MX2018004541 A MX 2018004541A
Authority
MX
Mexico
Prior art keywords
neoepitopes
immunotherapy
methods therefor
adaptive immunotherapy
patient
Prior art date
Application number
MX2018004541A
Other languages
English (en)
Inventor
Soon-Shiong Patrick
Nguyen Andrew
Niazi Kayvan
Charles Benz Stephen
Original Assignee
Nantomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics Llc filed Critical Nantomics Llc
Publication of MX2018004541A publication Critical patent/MX2018004541A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)

Abstract

Los tratamientos contra el cáncer contemplados comprenden el análisis recursivo de neoepítopes específicos del paciente, el cáncer y la ubicación de diversos sitios de biopsia de un paciente después del tratamiento o entre rondas sucesivas de inmunoterapia y/o quimioterapia para informar la inmunoterapia adicional. El análisis recursivo preferiblemente incluye diversos atributos de neoepítopes para identificar neoepítopes relevantes para el tratamiento.
MX2018004541A 2015-10-12 2016-10-12 Descubrimiento iterativo de neoepítopes e inmunoterapia adaptativa y método para ello. MX2018004541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562240482P 2015-10-12 2015-10-12
PCT/US2016/056668 WO2017066339A1 (en) 2015-10-12 2016-10-12 Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor

Publications (1)

Publication Number Publication Date
MX2018004541A true MX2018004541A (es) 2019-04-15

Family

ID=57886467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004541A MX2018004541A (es) 2015-10-12 2016-10-12 Descubrimiento iterativo de neoepítopes e inmunoterapia adaptativa y método para ello.

Country Status (11)

Country Link
US (3) US10532089B2 (es)
EP (2) EP3362797A4 (es)
JP (2) JP2018535202A (es)
KR (2) KR20180087246A (es)
CN (1) CN108700592B (es)
AU (1) AU2016339022B2 (es)
CA (1) CA3003305A1 (es)
HK (1) HK1258092A1 (es)
IL (1) IL258681B2 (es)
MX (1) MX2018004541A (es)
WO (1) WO2017066339A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717564B2 (en) 2015-10-12 2023-08-08 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3414692A4 (en) 2016-02-12 2020-07-29 Nantomics, LLC HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
US10534746B2 (en) * 2016-05-09 2020-01-14 Droplit, Inc. System and method for defining machine-to-machine communicating devices and defining and distributing computational tasks among same
IL311369A (en) * 2016-07-20 2024-05-01 BioNTech SE Selection of neoepitopes as disease-specific targets for therapy with increased efficacy
WO2018106699A1 (en) * 2016-12-08 2018-06-14 Nantbio, Inc. Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells
US20200166515A1 (en) * 2017-05-30 2020-05-28 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
US20200225229A1 (en) * 2017-09-25 2020-07-16 Nant Holdings Ip, Llc Validation of Neoepitope Presentation
WO2020023845A2 (en) * 2018-07-27 2020-01-30 Board Of Regents, The University Of Texas System Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer
CN110211633B (zh) * 2019-05-06 2021-08-31 臻和精准医学检验实验室无锡有限公司 Mgmt基因启动子甲基化的检测方法、测序数据的处理方法及处理装置
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
CN111951884B (zh) * 2020-07-10 2022-03-22 中南大学 蛋白质小分子结合口袋上关键柔性氨基酸的识别方法
EP4205121A2 (en) * 2020-08-28 2023-07-05 Envisagenics, Inc. Neoantigens, methods and detection of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2428941T3 (es) 2003-03-10 2013-11-12 Expression Pathology, Inc. Preparación líquida de tejidos a partir de muestras biológicas, tejidos y células procesadas histopatológicamente
CN100406061C (zh) * 2005-03-14 2008-07-30 博尔诚（北京）科技有限公司 调节性t细胞耗损剂在制备药物中的用途
CA3007805C (en) 2010-04-29 2019-11-26 The Regents Of The University Of California Pathway recognition algorithm using data integration on genomic models (paradigm)
US10192641B2 (en) 2010-04-29 2019-01-29 The Regents Of The University Of California Method of generating a dynamic pathway map
KR102447139B1 (ko) * 2010-05-14 2022-09-23 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
KR101952965B1 (ko) 2010-05-25 2019-02-27 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
EP2776959B1 (en) 2011-11-11 2021-08-11 Robert Beckman Personalized strategic cancer treatment
ES2737757T3 (es) 2012-09-28 2020-01-15 Univ Connecticut Identificación de epítopos protectores contra tumores para el tratamiento de cánceres
WO2014058687A1 (en) 2012-10-08 2014-04-17 Shell Oil Company Biomass conversion systems and methods for use thereof
CA2892308A1 (en) 2012-10-09 2014-04-17 Five3 Genomics, Llc Systems and methods for tumor clonality analysis
EP3417874A1 (en) * 2012-11-28 2018-12-26 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
CN105377292A (zh) * 2013-04-07 2016-03-02 博德研究所 用于个性化瘤形成疫苗的组合物和方法
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
NZ721908A (en) * 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US11145417B2 (en) 2014-02-04 2021-10-12 Optimata Ltd. Method and system for prediction of medical treatment effect
US20170045498A1 (en) 2014-04-25 2017-02-16 Diatech Oncology, Llc Intertumoral homogeneity determined by mick assay
RU2018106934A (ru) 2015-08-25 2019-09-26 Нантомикс, Ллс Системы и способы высокоточного определения вариантов
KR20180087246A (ko) 2015-10-12 2018-08-01 난토믹스, 엘엘씨 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
TW201722444A (zh) 2015-10-14 2017-07-01 艾***公司 重組李斯特菌疫苗菌株及在癌症免疫治療中使用該菌株之方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717564B2 (en) 2015-10-12 2023-08-08 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor

Also Published As

Publication number Publication date
EP3362797A1 (en) 2018-08-22
IL258681A (en) 2018-06-28
CN108700592B (zh) 2021-08-24
US11717564B2 (en) 2023-08-08
IL258681B2 (en) 2023-05-01
CN108700592A (zh) 2018-10-23
US20170028043A1 (en) 2017-02-02
AU2016339022A1 (en) 2018-05-10
KR20240010089A (ko) 2024-01-23
JP2018535202A (ja) 2018-11-29
EP3362797A4 (en) 2019-06-19
US10532089B2 (en) 2020-01-14
CA3003305A1 (en) 2017-04-20
WO2017066339A1 (en) 2017-04-20
WO2017066339A4 (en) 2017-06-22
EP3855444A1 (en) 2021-07-28
KR20180087246A (ko) 2018-08-01
US20230293651A1 (en) 2023-09-21
US20200113985A1 (en) 2020-04-16
HK1258092A1 (zh) 2019-11-01
AU2016339022B2 (en) 2020-09-10
JP2021178865A (ja) 2021-11-18
IL258681B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2018004541A (es) Descubrimiento iterativo de neoepítopes e inmunoterapia adaptativa y método para ello.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
PH12016501978A1 (en) Treatment of nafld and nash
SG10201913083SA (en) Methods of treating cancer with anti-tim-3 antibodies
NZ731467A (en) Anti-tim3 antibodies and methods of use
HK1253093A1 (zh) 診斷和治療癌症的方法
EP3630089A4 (en) PROCEDURE FOR CANCER THERAPY
EA201892487A1 (ru) Способ получения соединения диарилтиогидантоина
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
GEP20217331B (en) Anti-tigit antibodies
IL253979A0 (en) Methods, preparations and kits for cancer treatment
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
MX2022002365A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
EP3606531A4 (en) CANCER TREATMENT METHODS
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
IL272810A (en) Methods for diagnosing and treating lung cancer
IL291325A (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies and methods of use
MY181061A (en) Methods and apparatus for making molded objects, and molded objects made therefrom
EP3307913A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM
EP3723765A4 (en) CANCER TREATMENT METHODS